文献速递慢性静脉疾病

射频消融与氰基丙烯酸酯消融对比传统手术剥脱治疗静脉曲张的临床结果与成本效益

Clinical results and cost-effectiveness of radiofrequency and cyanoacrylate ablation compared with traditional surgical stripping for treating varicose veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-11-12

本研究纳入2016年2月至2019年2月两家医院血管科连续收治的症状性静脉曲张患者233例,比较手术剥脱(SS,n=90)、射频消融(RFA,n=93)与氰基丙烯酸酯消融(CAA,n=50)的3年结局。SS、RFA、CAA组并发症数分别为11例(12.2%)、3例(3.3%)、3例(6%)(P=.06),无患者需再次干预;社会视角下CAA最具成本效益,每例节省1600欧元,西班牙公共卫生系统视角下SS最具成本效益。

要点

  • SS、RFA、CAA组并发症数分别为11例(12.2%)、3例(3.3%)、3例(6%)(P=.06),无患者需再次干预。
  • SS、RFA、CAA组中位误工天数分别为15天(IQR 10-30)、0天(IQR 0-6)、0天(IQR 0-1)(P<.001)。
  • 社会视角下CAA最具成本效益,每例节省1600欧元;西班牙公共卫生系统视角下SS最具成本效益。

核心结论

  • 三种技术均具成本效益(增量成本效益比<€30,000/QALY的手术可被推荐)。
  • 从西班牙公共卫生系统视角仅考虑医疗成本时,SS最具成本效益。
  • 从社会视角纳入病假机会成本时,CAA最具成本效益,每例节省€1600,足以抵消SS在直接医疗成本上的节省。

研究设计与样本

  • 2016年2月至2019年2月两家医院血管科连续纳入的症状性静脉曲张患者233例,按实际接受的治疗分析。
  • 分组:SS组n=90(38.6%),RFA组n=93(39.9%),CAA组n=50(21.5%)。
  • 研究周期3年,未应用贴现率;费用统一换算为2020年5月美元与欧元。
  • 分析视角为社会视角与西班牙公共卫生系统视角,所有统计检验为双侧,显著性水平设为5%。

主要发现

  • SS、RFA、CAA组并发症数分别为11例(12.2%)、3例(3.3%)、3例(6%)(P=.06),无患者需再次干预。
  • SS、RFA、CAA组中位误工天数分别为15天(IQR 10-30)、0天(IQR 0-6)、0天(IQR 0-1)(P<.001)。
  • SS、RFA、CAA组中位满意度分别为9分(IQR 8-10)、10分(IQR 9-10)、10分(IQR 9-10)(P<.001)。
  • 三种手术的QALYs均为2.6年。
  • SS、RFA、CAA组中位总成本分别为€852(US$926)、€1002(US$1089)、€1228.3(US$1335);每QALY总成本分别为€323/QALY(US$351/QALY)、€380/QALY(US$413/QALY)、€467/QALY(US$508/QALY)。

关键数值与推荐

  • 增量成本效益比<€30,000/QALY的手术可被推荐(原文结论)。

临床怎么用

  • 原文结论指出三种技术均具成本效益,增量成本效益比<€30,000/QALY的手术可被推荐。
  • 从西班牙公共卫生系统视角仅考虑医疗成本时,SS最具成本效益。
  • 从社会视角纳入病假机会成本时,CAA最具成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disease of the venous system is an underappreciated public health problem. Minimally invasive treatments such as radiofrequency ablation (RFA) or cyanoacrylate adhesive ablation (CAA) have almost entirely replaced surgical stripping (SS) of the great and small saphenous veins. The purpose of the present study was to compare the outcomes at 3 years after SS, RFA, and CAA by assessing the incidence of complications and reinterventions and performing a cost-effectiveness analysis. METHODS: From February 2016 to February 2019, all consecutive patients with symptomatic varicose veins treated at vascular department of two hospitals using SS, RFA, or CAA were included in the present study. The clinical outcomes were measured by quality-adjusted life years (QALYs), complications, and reintervention. A comparison with conservative treatment was also performed. A detailed resource use was recorded for each procedure. All costs were normalized to May 2020 U.S. dollars and euros. Analysis of the data was by the treatment received. All statistical tests were two-sided, and the significance level was set at 5%. Two perspectives of the analysis were considered: the social perspective and that of the Spanish Public Health System. The study period was 3 years. No discount rate was applied. RESULTS: A total of 233 patients were enrolled in the present study: SS, n = 90 (38.6%); RFA, 93 (39.9%); and CAA, n = 50 (21.5%). The number of complications was 11 (12.2%), 3 (3.3%), and 3 (6%) in the SS, RFA, and CAA groups, respectively (P = .06). No patient had required reintervention. The median loss of workdays for the SS, RFA, and CAA group was 15 days (interquartile range [IQR], 10-30 days), 0 days (IQR, 0-6 days), and 0 days (IQR, 0-1 days), respectively (P < .001). The median level of satisfaction for the SS, RFA, and CAA group was 9 (IQR, 8-10), 10 (IQR, 9-10), and 10 (IQR, 9-10), respectively (P < .001). The QALYs was 2.6 years for all three procedures. The median overall cost was €852 (US$926) for SS, €1002 (US$1089) for RFA, and €1228.3 (US$1335) for CAA. The total cost per QALY was €323/QALY (US$351/QALY) for SS, €380/QALY (US$413/QALY) for RFA, and €467/QALY (US$508/QALY) for CAA. The indirect costs were measured by the cost of the workdays lost for each patient and were €1527 (US$1660; IQR, €1018-3054); €0 (IQR, €0-611) for RFA, and €0 (IQR, €0-102) for CAA (P < .001). CONCLUSIONS: All three techniques were cost-effective (procedures with an incremental cost-effectiveness ratio <€30,000/QALY can be recommended). From the Spanish Public Health System perspective, when considering only the health care costs, the most cost-effective technique was SS. From the social perspective, including the opportunity costs of medical leave, CAA was the most cost-effective technique, saving €1600 per patient, a cost that more than compensated for the savings realized from using SS in direct health care costs.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Vicente-Jiménez S, Lopez-Valcarcel B, Maynar M, et al. Clinical results and cost-effectiveness of radiofrequency and cyanoacrylate ablation compared with traditional surgical stripping for treating varicose veins. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34781007. doi:10.1016/j.jvsv.2021.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。